miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 15, 2026

Walmart earnings, spending data, and more AI disruptions: What to watch this week

View original at finance.yahoo.com
Walmart earnings, spending data, and more AI disruptions: What to watch this week AI turbulence was the dominant theme in markets last week, with software, real estate, financial services, and logistics stocks all facing selling pressure on worries about the scale of AI-related disruption to their businesses…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The timing of AI disruption remains indeterminate, and the fog of uncertainty is unlikely to dissipate quickly

    80% confidence
  • The glaring theme underneath the surface for not just Tech, but for every corner of the market right now is an aggressive shoot first ask questions later for any area of the market that has an AI headline

    80% confidence
  • Every rose has its thorn - economic data was not without flaws

    80% confidence
  • This environment of relatively strong growth, juiced by higher tax refunds from the One Big Beautiful Bill Act, an improving job market and a continued trend of lower inflation will keep interest rates in a steady range as we await Kevin Warsh's fresh perspective at the Fed

    80% confidence
  • The AI disruption-led selloff in February has been driven by the legitimate belief that AI-driven change is coming faster not only to software, but to many other sectors

    80% confidence
  • The categories that surprised to the upside in CPI — non-vehicle goods and non-shelter services — are the ones that matter most for inflation persistence

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,985
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,985 hechos verificados con la fuente5,351 documentos fuente archivados
Consulta estos datos → isubstrate.com